CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

June 11, 2024

https://www.globenewswire.com/news-release/2024/06/11/2896702/0/en/CervoMed-Announces-Completion-of-Enrollment-in-Phase-2b-RewinD-LB-Clinical-Trial-of-Neflamapimod-for-the-Treatment-of-Patients-with-Dementia-with-Lewy-Bodies.html

– Topline data expected in December 2024 –

– Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.